Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma

23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)

(2015) F.S. Hodi et al.   EUROPEAN JOURNAL OF CANCER

Administration of Ipilimumab to a Liver Transplant Recipient With Unresectable Metastatic Melanoma

(2015) Harsha A. Ranganath et al.   JOURNAL OF IMMUNOTHERAPY

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation

(2015) Rita E Morales et al.   Journal for ImmunoTherapy of Cancer

Successful Administration of Ipilimumab to Two Kidney Transplantation Patients With Metastatic Melanoma

(2014) Evan J. Lipson et al.   JOURNAL OF CLINICAL ONCOLOGY

Ipilimumab in patients with melanoma and autoimmune disease

(2014) Chrisann Kyi et al.   Journal for ImmunoTherapy of Cancer

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

(2012) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Radiation as an immunological adjuvant: current evidence on dose and fractionation

(2012) Sandra Demaria et al.   Frontiers in Oncology

Melanoma in Solid Organ Transplant Recipients

(2010) F. O. Zwald et al.   AMERICAN JOURNAL OF TRANSPLANTATION

The PD-1 pathway in tolerance and autoimmunity

(2010) Loise M. Francisco et al.   IMMUNOLOGICAL REVIEWS

Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses

(2010) Astrid Starke et al.   KIDNEY INTERNATIONAL